Marker Therapeutics Inc (MRKR)vsModerna Inc (MRNA)
MRKR
Marker Therapeutics Inc
$1.01
+1.00%
HEALTHCARE · Cap: $16.01M
MRNA
Moderna Inc
$222.76
+4.01%
HEALTHCARE · Cap: $85.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 62719% more annual revenue ($2.23B vs $3.55M). MRNA leads profitability with a -141.4% profit margin vs -245.5%. MRKR earns a higher WallStSmart Score of 22/100 (F).
MRKR
Avoid22
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MRKR.
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$222.76
$88.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -77.0% — below average capital efficiency
Trading at 13.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRKR
The strongest argument for MRKR centers on Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MRKR
The primary concerns for MRKR are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MRKR carries more volatility with a beta of 1.53 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MRKR generates stronger free cash flow (-4M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRKR scores higher overall (22/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Marker Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?